Published in Breast Cancer Res on November 04, 2004
Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia (2007) 0.91
A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics (2008) 0.83
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition. PLoS One (2013) 0.81
High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study. BMC Cancer (2012) 0.81
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. Br J Cancer (2007) 0.80
Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients. Cancer Cell Int (2014) 0.76
Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res (1997) 4.61
The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med (2003) 1.84
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol (2001) 1.68
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res (2003) 1.02
A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer (2001) 1.02
Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer (2002) 1.01
High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol (2002) 1.01
Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). Leuk Lymphoma (1993) 0.83
Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leuk Lymphoma (1995) 0.81
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol (2013) 1.59
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem (2013) 1.58
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood (2013) 1.54
Prevalence of the burnout syndrome among Brazilian medical oncologists. Rev Assoc Med Bras (2007) 1.42
[Acceptance of chemotherapy by Brazilian women with breast cancer]. Rev Assoc Med Bras (2006) 1.40
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. Rev Bras Hematol Hemoter (2012) 1.22
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol (2013) 1.14
Negative results in cancer clinical trials--equivalence or poor accrual? Control Clin Trials (2004) 1.12
Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol (2004) 1.12
Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie (2009) 1.12
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant (2010) 1.10
Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol (2009) 1.07
The biology of cancer-related fatigue: a review of the literature. Support Care Cancer (2015) 1.02
Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer (2010) 0.98
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. Rev Bras Hematol Hemoter (2013) 0.97
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood (2014) 0.96
Weight changes during chemotherapy for breast cancer. Sao Paulo Med J (2002) 0.96
Ancient schwannoma of the vagus nerve, resection with continuous monitoring of the inferior laryngeal nerve. Braz J Otorhinolaryngol (2008) 0.95
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol (2014) 0.93
Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy. Adv Hematol (2010) 0.89
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2012) 0.88
Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia. Acta Haematol (2010) 0.88
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Blood Disord (2010) 0.87
Simultaneous occurrence of Hodgkin disease and tuberculosis: report of three cases. South Med J (2004) 0.87
Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. Acta Haematol (2012) 0.86
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol (2015) 0.85
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol (2008) 0.85
Effects of selective bile duct ligation on liver parenchyma in young animals: histologic and molecular evaluations. J Pediatr Surg (2012) 0.85
Effectiveness of guaraná (Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study. J Altern Complement Med (2009) 0.84
Testicular lymphoma. Semin Oncol (2010) 0.84
Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer (2011) 0.83
Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer (2005) 0.81
Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better. Support Care Cancer (2007) 0.81
Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Des Devel Ther (2013) 0.81
Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res (2003) 0.81
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol (2014) 0.80
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. Eur J Haematol (2012) 0.79
Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC. Sao Paulo Med J (2005) 0.79
Purified dry extract of Paullinia cupana (guaraná) (PC-18) for chemotherapy-related fatigue in patients with solid tumors: an early discontinuation study. J Diet Suppl (2013) 0.79
Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. Pediatr Blood Cancer (2010) 0.79
Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leuk Lymphoma (2012) 0.79
Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failure. Br J Haematol (2010) 0.79
Mdm2 mRNA expression in salivary gland tumour cell lines. J Oral Pathol Med (2004) 0.78
Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia. Cancer Genet (2011) 0.78
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response. Rev Bras Hematol Hemoter (2011) 0.78
Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori (2005) 0.77
Early Detection of t(8;21) Chromosomal Translocations During Treatment of PML-RARA Positive Acute Promyelocytic Leukemia: A Case Study. Clin Med Insights Oncol (2010) 0.77
Ethnic differences in cerebral venous thrombosis. Cerebrovasc Dis (2005) 0.76
Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumour Biol (2013) 0.76
Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol (2010) 0.76
Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Leuk Lymphoma (2014) 0.76
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. Am J Clin Oncol (2009) 0.76
Erratum to: The biology of cancer-related fatigue: a review of the literature. Support Care Cancer (2015) 0.76
Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer (2002) 0.76
Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J (2004) 0.75
Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study. Support Care Cancer (2009) 0.75
Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen. Br J Haematol (2009) 0.75
Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol (2010) 0.75
Non-neoplastic bulky mediastinal mass presentation in an adolescent patient: a case report. J Med Case Rep (2013) 0.75
Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors. Cancer (2013) 0.75
Is there publication bias towards Brazilian articles on cancer? Einstein (Sao Paulo) (2013) 0.75
The use of imatinib mesylate as a lifesaving treatment of chronic myeloid leukemia relapse after bone marrow transplantation. J Transplant (2009) 0.75
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Invest (2015) 0.75
Woman with a papillary pulmonary lesion and a complex renal cyst. Oncology (Williston Park) (2006) 0.75
Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori (2007) 0.75
Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia. Pediatr Blood Cancer (2008) 0.75
[Good, pretty and cheap]. Rev Assoc Med Bras (2005) 0.75
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol (2011) 0.75
Simultaneous occurrence of biphenotypic T cell/myeloid lesions involving t(12;13)(p13;q14) in a pediatric patient. Acta Haematol (2012) 0.75
Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials. Support Care Cancer (2006) 0.75
A phase I study of gemcitabine combined with vinblastine in patients with solid tumors. Tumori (2003) 0.75
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor. Transfusion (2014) 0.75
HSP27 is commonly expressed in cervical intraepithelial lesions of Brazilian women. Asian Pac J Cancer Prev (2013) 0.75
Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors. Int J Hematol (2008) 0.75
Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia. Acta Haematol (2011) 0.75
[Medicine and humanism]. Rev Assoc Med Bras (2007) 0.75
Primary testicular lymphoma and AIDS. Ann Clin Lab Sci (2010) 0.75